Diagnostics

Zero Candida Receives South African Patent for its ZC- 01 device

Announces IP plans to obtain a worldwide patent portfolio in 2025 VANCOUVER, BC, Dec. 9, 2024 /PRNewswire/ -- Zero Candida…

2 weeks ago

Cytovale Recognized as One of Modern Healthcare’s 2024 Best in Business

Company's IntelliSep® rapid sepsis detection solution recognized for helping hospitals save lives and money while delivering patient-centered care SAN FRANCISCO, Dec.…

2 weeks ago

Cala® Health Closes Oversubscribed $50 Million Financing To Propel Growth

SAN MATEO, Calif., Dec. 9, 2024 /PRNewswire/ -- Cala Health, the non-invasive bioelectronic medicine leader, today announced it has completed…

2 weeks ago

T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens

Intends to accelerate broad adoption of direct-from-whole-blood diagnostics, generate non-dilutive capital, and create a new royalty revenue streamLEXINGTON, Mass., Dec.…

2 weeks ago

Spectral AI Incorporates Frontline Feedback into Improved Software Release for Enhanced Diagnostic Precision

DALLAS, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI)…

2 weeks ago

Senseonics Holdings, Inc. Provides Update on Eversense 365 Launch

Strong Eversense® 365 early launch indicators illustrated by largest number of new patient shipments and largest number of prescribing providers…

2 weeks ago

Nature Methods Names Spatial Proteomics “Method of the Year 2024” — Akoya Biosciences Celebrates Industry Milestone

MARLBOROUGH, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, announced that…

2 weeks ago

CeraVx B.V. Emerges from Stealth Acquires Micro Needle Technology from MLT Appoints Management and Supervisory Board

CeraVx BV successful bid to acquire key micro needle technology from MLTManagement team:Dr. Jan Groen as CEO,Dinja Oosterhof , PhD…

2 weeks ago

Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions

New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL Studies…

2 weeks ago